By Kit Norton

Shares of Organon & Co soared at the opening bell on Friday after a report said that Sun Pharmaceutical Industries had submitted a binding offer of $12 billion for the women's healthcare company.

The Economic Times, an Indian English-language business publication, reported Friday that the India-based Sun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon, which is based in New Jersey. The deal would be an all-cash offer, according to the report.

Neither Organon nor Sun Pharmaceutical Industries immediately responded to request for comment from Barron's.

Organon stock surged 41% to $8.25 at the opening bell on Friday after rising 18% to $6.91 on Thursday. Organon has a market capitalization of $1.8 billion.

Organon was spun off from Merck in 2021 and develops therapies for reproductive health, contraception, and fertility. The company also has a portfolio of biologic drugs and brands for dermatology, neurology, and cardiovascular conditions.

In October 2025, Organon CEO Kevin Ali resigned after an internal board investigation found what the drugmaker called improper sales practices aimed at boosting quarterly results in recent years.

Write to Kit Norton at kit.norton@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

April 10, 2026 10:01 ET (14:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.